Trial · NCT02717455
Adverse events666
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
441 to 460 of 666
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash acneiform | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 1 (16 mg/m^2) | 0 | 3 | 0 |
| other | Rash acneiform | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 2 (22 mg/m^2) | 1 | 11 | 1 |
| other | Rash acneiform | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 3 (28 mg/m^2) | 0 | 12 | 0 |
| other | Rash acneiform | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 4 (36 mg/m^2) | 0 | 6 | 0 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Stratum 1, Dose Level 1 (10 mg/m^2) | 0 | 13 | 0 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Stratum 1, Dose Level 2 (16 mg/m^2) | 1 | 6 | 1 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 1 (16 mg/m^2) | 0 | 3 | 0 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 2 (22 mg/m^2) | 1 | 11 | 1 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 3 (28 mg/m^2) | 0 | 12 | 0 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 4 (36 mg/m^2) | 0 | 6 | 0 |
| other | Skin and subcutaneous tissue disorders - other, specify | Skin and subcutaneous tissue disorders | Stratum 1, Dose Level 1 (10 mg/m^2) | 2 | 13 | 2 |
| other | Skin and subcutaneous tissue disorders - other, specify | Skin and subcutaneous tissue disorders | Stratum 1, Dose Level 2 (16 mg/m^2) | 0 | 6 | 0 |
| other | Skin and subcutaneous tissue disorders - other, specify | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 1 (16 mg/m^2) | 0 | 3 | 0 |
| other | Skin and subcutaneous tissue disorders - other, specify | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 2 (22 mg/m^2) | 0 | 11 | 0 |
| other | Skin and subcutaneous tissue disorders - other, specify | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 3 (28 mg/m^2) | 0 | 12 | 0 |
| other | Skin and subcutaneous tissue disorders - other, specify | Skin and subcutaneous tissue disorders | Stratum 2, Dose Level 4 (36 mg/m^2) | 0 | 6 | 0 |
| other | Flushing | Vascular disorders | Stratum 1, Dose Level 1 (10 mg/m^2) | 0 | 13 | 0 |
| other | Flushing | Vascular disorders | Stratum 1, Dose Level 2 (16 mg/m^2) | 0 | 6 | 0 |
| other | Flushing | Vascular disorders | Stratum 2, Dose Level 1 (16 mg/m^2) | 1 | 3 | 1 |
| other | Flushing | Vascular disorders | Stratum 2, Dose Level 2 (22 mg/m^2) | 0 | 11 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02717455/events?page=23